Results 171 to 180 of about 4,927,968 (256)

Turning Bonding Into Function: The Emerging Role of the Bioactive Selenium─Metal Motif in Toxicology and Medicinal Chemistry

open access: yesChemistry – A European Journal, EarlyView.
Balancing Act: Se─M bond serving as the fulcrum of the balance scale to compare the different weight of toxicity and therapeutic effects in biological environment. ABSTRACT The synthesis and characterization of organo‐selenium compounds have attracted considerable interest for decades, driven by the search for efficient catalysts and bioinspired ...
Matteo Filippi   +6 more
wiley   +1 more source

The secretory protein, CLCF1, improves cholestatic liver disease by inhibiting hepatic bile acid synthesis and promoting bile acid excretion. [PDF]

open access: yesCommun Biol
Liu M   +12 more
europepmc   +1 more source

The synthesis of fluorinated bile acid analogues

open access: yes, 2019
Bile acids are a type of acidic steroid found in the bile of mammals and other vertebrates. They are key in the digestion of food but also play a role as signalling molecules, regulating their own synthesis and transport, as well as being involved in the
Wynn, Rachel
core  

Thiamine Diphosphate‐Dependent Biocatalysis in the 21st Century

open access: yesChemistry – A European Journal, EarlyView.
This account summarizes the major discoveries and recent advances, highlighting the biocatalytic abilities, mechanistic studies, and feature‐based classification that are shaping emerging perspectives on thiamine diphosphate (ThDP)‐dependent catalysis.
Lucrezia Lanza   +2 more
wiley   +1 more source

The Diagnostic Saga of a Rare Congenital Bile Acid Synthesis Disorder: A Case Report. [PDF]

open access: yesClin Med Insights Pediatr
Yazbeck N   +3 more
europepmc   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy